Tuesday, April 19th, 2011
Biofortuna Ltd, a UK-based molecular diagnostics company, today announced that they have signed an exclusive distribution agreement with Abbott’s molecular diagnostics business, whereby Biofortuna will design, develop and manufacture a range of freeze-dried HLA-typing kits called SSPGo. Financial terms have not been disclosed.
Monday, March 21st, 2011
Biofortuna Ltd, the UK based molecular diagnostics company specialising in its proprietary freeze-dried diagnostics, today announces the immediate appointment of Dr Simon Douglas as Chief Executive Officer. The move allows Dr Mike Bunce, who jointly held the position of CEO and CSO to focus as the CSO.
Friday, February 4th, 2011
Biofortuna has raised £1 million ($1.6 million), which it will use to develop a market for its diagnostic genotyping products and new products.
Monday, September 27th, 2010
UK-based molecular diagnostics company Biofortuna Limited has unveiled the world’s first complete freeze-dried HLA PCR kit in a move set to transform the transplantation market.
Monday, September 13th, 2010
SAN DIEGO (September 14, 2010) – TriLink BioTechnologies, Inc. (TriLink) announced that it has signed a licensing agreement with Biofortuna Ltd. (Biofortuna) for use of CleanAmp™ dNTPs in Biofortuna’s freeze dried in vitro diagnostic PCR kits.
Friday, May 14th, 2010
UK-based venture and growth capital funds EV and Catapult Venture announced that they have provided funding to Liverpool-based molecular diagnostics company, Biofortuna Limited.
The funding will be used to launch the company’s first diagnostic genotyping products and to allow it to continue development of its future product pipeline.
The management team is led by CEO Mike Bunce [...]
Monday, November 16th, 2009
Lab901 (Edinburgh, UK) and Biofortuna (Liverpool, UK) today announced that they will collaborate on the launch of an automated PCR based diagnostics system for the rapid detection of certain HLA-related diseases such as Coeliac disease. Lab901 will be optimising its automated ScreenTape® PCR diagnostics platform for use with Biofortuna’s range of multiplex PCR diagnostics kits [...]
Friday, November 13th, 2009
Biofortuna were today approved by Lloyds Register Quality Assurance for the design and manufacture of genotyping and phenotyping in-vitro diagnostic products which enables us to sell CE marked products.
The rapid progress in quality management is testament to the dedication and skill of our quality team and our consultant Dave Ashworth from Flintloque Management Systems.
(See also [...]
Friday, November 13th, 2009
Over 200 people from the Northwest’s biomedical sector gathered last night (Thursday 12th November) at the prestigious annual Northwest Biomedical Awards at Mere Golf and Country Club. The awards, organised by Bionow, the Northwest Regional Development Agency’s (NWDA) biomedical cluster support group, were a resounding success and showcased the very best of the region’s world [...]
Wednesday, March 4th, 2009
Biofortuna secure an offer of £94,558 from the Northwest Development Agency in a grant for Research & Development. The grant will enable Biofortuna to develop a novel DNA genotyping method that has the potential to allow healthcare professionals to look at multiple gene mutations simultaneously in one rapid test.
(Also featured in the Bionow May newsletter)
Registered address: Sumner House, St Thomas's Road, Chorley, Lancashire, PR7 1HP
Registered number: 06514391
© 2012 Biofortuna Limited
